Human TIM-3 / HAVCR2 Protein
- Known as:
- Human TIM-3 / HAVCR2 Protein
- Catalog number:
- TM3-H5229
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human TIM-3 / HAVCR2 Protein
Related genes to: Human TIM-3 / HAVCR2 Protein
- Gene:
- HAVCR2 NIH gene
- Name:
- hepatitis A virus cellular receptor 2
- Previous symbol:
- -
- Synonyms:
- Tim-3, TIM3, FLJ14428, TIMD3, CD366
- Chromosome:
- 5q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-12-04
- Date modifiied:
- 2018-06-27
Related products to: Human TIM-3 / HAVCR2 Protein
Related articles to: Human TIM-3 / HAVCR2 Protein
- Metastatic melanoma is an aggressive, heterogeneous cancer with early spread and poor prognosis. Transcriptomic analysis identifies potential therapeutic targets. In silico analysis of the GEO dataset GSE7553 compared primary vs metastatic melanoma using differential expression, enrichment (GO/KEGG/Reactome), PPI network construction, and hub-gene prioritization. Candidates were validated through survival analysis, mutation-associated analyses, and virtual screening using molecular docking with FDA-approved compounds. Transcriptomic results show divergence between primary and metastatic melanoma samples, with principal component analysis supporting clear group separation. In a total of 54,675 probe-level entries, 4868 were classified as upregulated and 10,269 as downregulated, indicating a predominance of downregulated transcriptional events in metastatic melanoma. Prioritized upregulated genes included CUL5, ZC3H14, SON, BRCC3, and H3-3B, whereas notable downregulated genes included ZNF709, CD84, STARD8, EPOR, and HAVCR2. The high-confidence PPI network comprised 625 nodes and 2661 edges, with a significant enrichment score. Enrichment analysis implicated immune/adhesion and translation pathways (e.g., Rap1, focal adhesion, T-cell activation). Survival: CUL5 (HR = 0.26) and ZC3H14 (HR = 0.60) are protective, while SON (HR = 2.4) is adverse. Mutation-linked transcriptomic analysis identified 10 significantly altered genes, including downregulated SNHG18 and upregulated LPCAT2. Virtual screening results show repurposable compounds, with Floxacrine showing strong predicted affinity for CUL5 and Dihydroergocristine showing favorable interaction with LPCAT2/ZC3H14-related targets. In silico docking results further supported CUL5-Floxacrine and LPCAT2-Dihydroergocristine as notable candidate interactions. Results show key transcriptomic drivers and targets (CUL5, ZC3H14, SON, BRCC3, LPCAT2) in metastatic melanoma. Results highlight a useful hypothesis-generating framework for biomarker prioritization and drug repurposing in melanoma. However, independent cohort validation and experimental confirmation are required before clinical translation. - Source: PubMed
Publication date: 2026/05/02
Majeed Khulood AyadMajeed Raghad AyadIbrahim Taisir KhalilKhan Najeeb Ullah - Colorectal cancer (CRC) remains the leading cause of cancer-related mortality worldwide and necessitates the development of novel therapeutic strategies. The tumor immune microenvironment (TME) critically influences disease progression and the response to immune checkpoint inhibitors (ICIs). Tumor-infiltrating lymphocytes (TILs) are key components of the TME with established prognostic and predictive significance. Nevertheless, detailed TIL characterization using flow cytometry has not been fully investigated in CRC. - Source: PubMed
Matoba DaijiroSaito TakuroNoda TakehiroUemura MamoruUeyama AzumiWada HisashiDoki YuichiroEguchi Hidetoshi - Survival outcomes for pediatric Burkitt lymphoma (BL) substantially vary depending on geography (50-90%), which also serves as a proxy for the prevalence of Epstein-Barr virus (EBV) within the tumors. Although BL is considered an immunologically "cold" tumor with few tumor-infiltrating lymphocytes (TILs), their functional status has not been fully evaluated, especially for EBV-positive disease. Here, we characterize the exhaustion and activation profiles of T cells in the tumor microenvironment (TME) of EBV-positive BL using orthogonal methods, single-cell gene expression analysis, spectral flow cytometry, and immuno-histochemistry staining (IHC). We found that CD8+ TILs displayed a mosaic of immune inhibitory gene expression encoding, PD1, TIGIT, LAG3 and HAVCR2/TIM3. IHC validated the expression of PD1 and TIGIT on CD8+ TILs, as well as their respective ligands, PDL-1, PVR, and Nectin-2 on malignant B cells. Despite exhaustion-associated signatures, CD8+ TILs retain cytotoxic potential, expressing granules (i.e. Granzyme A, Perforin) and cytokines (i.e. IFNγ) and demonstrate an increased uptake of metabolites such as glucose, arginine, and methionine. In peripheral blood, pediatric BL patients exhibited a significantly higher abundance of PD1+TIGIT+ CD8+ T cells compared to healthy children. Notably, these circulating T cells from BL patients express significantly lower levels of TOX, suggesting they are not irreversibly dysfunctional. Together, our results indicate that CD8+ T cells both in the TME and in circulation of children with BL are not terminally exhausted but remain poised for functional re-invigoration. These findings support the potential integration of immune checkpoint inhibitors into combination chemotherapeutic regimens to improve outcomes for these children. - Source: PubMed
Publication date: 2026/04/19
Forconi Catherine SOduor Cliff ISaikumar Priya LRacenet Zachary JFujimori GavinM'Bana ViriatoMatta AngelaMelo JeniLaderach FabienneMaina Titus KOtieno Juliana AChepsidor DanKibor KibetNjuguna FestusVik TerryKinyua Ann WMunz ChristianBailey Jeffrey AMoormann Ann M - Pregnancy is characterized by significant changes in peripheral immunity. Total CD3+ T cells decrease across pregnancy while Forkhead Box P3+ T-regulatory cells (FoxP3+Tregs) peak in mid-pregnancy, the latter of which are key to healthy outcomes. However, less is known regarding distinct memory populations of FoxP3+ Tregs and their phenotypic changes across pregnancy. - Source: PubMed
Mulugeta NolawitPeters M QuinnTobey CaraWong JiaSpray Abigail L PArmistead BlairJiang YonghouKatz RonitShree RajVojtech LuciaHarrington Whitney E - Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single day production of non-activated CAR T-cells engineered to secrete interleukin-18 (IL-18), a pro-inflammatory cytokine that enhances T-cell function. These non-activated CART-IL18 cells exhibit robust anti-tumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like non-activated CAR T-cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18-enhanced, activation-free CAR T product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T. - Source: PubMed
Publication date: 2026/04/16
Durgin Joseph SSeo Shin HKazmi ShadabValentić BakirLeff ChloeMarkovska MartinaJin XiaolingShen FengBerjis AbdullaMukherjee NandanaSannecy AshwinPlesa GabrielaGabunia KhatunaScholler JohnGill Saar IO'Connor Roddy SJune Carl HGhassemi Saba